InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase (BTK) inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma (ICML).
BEIJING--(BUSINESS WIRE)--Blood Advances, part of leading hematology journal Blood, also a Journal of the American Society of Hematology, recently published the clinical study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL) patients. The journal concluded that orelabrutinib showed substantial efficacy and was well tolerated in patients with r/r MCL after long-term follow-up.
Biogen has given up on orelabrutinib, an BTK inhibitor for the potential treatment of multiple sclerosis, after paying $125 million for it in 2021.
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
China’s Center for Drug Evaluation (CDE) has granted approval for InnoCare Pharma to conduct a Phase II clinical trial of orelabrutinib along with tafasitamab + lenalidomide to treat Non-Hodgkin’s lymphoma (NHL).
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore